Qiagen NV (NASDAQ:QGEN) – Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for shares of Qiagen in a research note issued on Friday, according to Zacks Investment Research. Jefferies Group analyst P. Welford anticipates that the company will post earnings of $0.25 per share for the quarter. Jefferies Group also issued estimates for Qiagen’s Q2 2018 earnings at $0.32 EPS, Q3 2018 earnings at $0.35 EPS, Q4 2018 earnings at $0.44 EPS and FY2022 earnings at $2.26 EPS.
A number of other equities analysts also recently issued reports on QGEN. Commerzbank restated a “buy” rating on shares of Qiagen in a research report on Thursday, February 1st. TheStreet downgraded Qiagen from a “b-” rating to a “c+” rating in a report on Thursday, February 8th. Zacks Investment Research upgraded Qiagen from a “sell” rating to a “hold” rating in a report on Tuesday, February 6th. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a report on Monday, January 22nd. Finally, Morgan Stanley lifted their target price on Qiagen from $38.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $35.33.
Qiagen (NASDAQ QGEN) opened at $31.90 on Monday. Qiagen has a 1 year low of $27.74 and a 1 year high of $36.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07. The stock has a market capitalization of $7,260.12, a PE ratio of 187.25, a PEG ratio of 1.93 and a beta of 1.03.
Qiagen announced that its Board of Directors has approved a share buyback plan on Wednesday, January 31st that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its stock is undervalued.
Institutional investors have recently made changes to their positions in the business. American International Group Inc. acquired a new stake in Qiagen in the fourth quarter valued at approximately $154,000. Quadrant Capital Group LLC grew its stake in Qiagen by 4.1% in the second quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after acquiring an additional 225 shares during the period. Lourd Capital LLC acquired a new stake in Qiagen in the fourth quarter valued at approximately $223,000. Koch Industries Inc. acquired a new stake in Qiagen in the second quarter valued at approximately $231,000. Finally, Hartford Investment Management Co. acquired a new stake in Qiagen in the third quarter valued at approximately $231,000. 62.23% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/jefferies-group-weighs-in-on-qiagen-nvs-q1-2018-earnings-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Get a free copy of the Zacks research report on Qiagen (QGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.